Exploring Key Insights of the Acquired Immunodeficiency Syndrome (AIDS) Market: Growth Prospects, Emerging Trends, and Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the acquired immunodeficiency syndrome (aids) market grown over the years?
The market size for acquired immunodeficiency syndrome (AIDS) has seen substantial growth in recent times. The market is projected to surge from $32.09 billion in 2024 to $33.85 billion in 2025, experiencing a compound annual growth rate (CAGR) of 5.5%. The historical growth can be linked to the escalating HIV infection rates, amplified government funds for HIV care, expansion of international awareness programs, betterment in diagnostic capabilities, and increased assistance from non-governmental organizations.
What Is the forecasted market size and growth rate for the acquired immunodeficiency syndrome (aids) market?
There’s anticipated to be substantial growth in the acquired immunodeficiency syndrome (AIDS) market in the coming years. The market is predicted to expand to $41.57 billion by 2029, with a compound annual growth rate (CAGR) of 5.3%. This projected increase is due to factors such as the increasing need for long-acting injectable therapies, more widespread use of pre-exposure prophylaxis (PrEP), increased funding for HIV cure research, the expansion of remote healthcare services for HIV patients, increased emphasis on personalized medicine, and increased awareness of early HIV detection. Future trends include a migration towards single-tablet regimes, a growing preference for injectable and implantable HIV treatments, a surge in demand for digital health solutions for managing HIV, a growing commitment to functional HIV cure strategies, and the growing application of artificial intelligence in drug discovery.
Get your acquired immunodeficiency syndrome (aids) market report here!
What are the major factors driving growth in the acquired immunodeficiency syndrome (aids) market?
The surge in HIV infection rates is anticipated to stimulate growth in the acquired immunodeficiency syndrome (AIDS) market. HIV infections, caused by the human immunodeficiency virus (AIDS), undermine the immune system, reducing the body’s ability to combat ailments. The rising occurrence of HIV is linked to unprotected sex with an infected individual, needle or syringe sharing, receiving contaminated blood, having several sexual partners, or a diminished immune system, as well as pre-existing STDs. AIDS management assists HIV patients by encouraging early detection, broadening access to powerful antiretroviral therapies, amplifying precautionary measures, and fortifying healthcare systems, all of which contribute to more effective control of the virus. For example, data released by the European Centre for Disease Prevention and Control (ECDC) in November 2024, a Sweden-based European Union agency, disclosed a total of 112,883 HIV diagnoses in 2023, covering 47 out of 53 countries in the region, and 24,731 cases were registered in the European Union/European Economic Area (EU/EEA). The overall crude HIV diagnosis rate stood at 12.7 per 100,000 population, a 2.4% increase from the rate of 12.4 per 100,000 seen in 2022. Consequently, the escalation in HIV infections is fuelling the acquired immunodeficiency syndrome (AIDS) market.
What key areas define the segmentation of the global acquired immunodeficiency syndrome (aids) Market?
The acquired immunodeficiency syndrome (AIDS) market covered in this report is segmented –
1) By Type: Human Immunodeficiency Virus 1, Human Immunodeficiency Virus 2
2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Fusion Inhibitors, CCR5 Anatagonists And Post-Attachment Inhibitors, Protease Inhibitors, Integrase Inhibitors, Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis
3) By Route Of Administration: Oral, Parenteral
4) By Application: Hospital Pharmacy, Retail Pharmacy, Other Applications
5) By Distribution Channel: Offline, Online
Subsegments:
1) By Human Immunodeficiency Virus 1 (HIV-1): Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), HIV-1 Diagnostic Tests, HIV-1 Vaccine Development, HIV-1 Opportunistic Infection Management
2) By Human Immunodeficiency Virus 2 (HIV-2): Antiretroviral Therapy (ART) For HIV-2, HIV-2 Diagnostic Tests, HIV-2 Surveillance And Epidemiology, HIV-2 Vaccine Research, Management Of HIV-2 Co-Infections
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21076&type=smp
What are the top market players propelling the growth of the acquired immunodeficiency syndrome (aids) industry?
Major companies operating in the acquired immunodeficiency syndrome (AIDS) market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatris Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy’s Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, ViiV Healthcare
What are the key trends shaping the future of the acquired immunodeficiency syndrome (aids) market?
Leading firms in the acquired immunodeficiency syndrome (AIDS) market are prioritizing the creation of innovative therapies such as long-acting injectables. These treatment options are aimed at enhancing patient conformity, lowering the need for constant dosing and serving as a more convenient substitute to daily oral antiretroviral medications. Long-acting injectables are drugs given via injection, configured to slowly discharge their active ingredients over a prolonged period. This allows for less consistent dosing compared to conventional oral drugs. For instance, GSK plc, a UK-based drug company, announced in January 2025 that it had received approval from the European Commission to distribute the long-acting injectable treatment known as Vocabria (cabotegravir) and Rekambys (rilpivirine). This therapy is accepted for use in adolescents aged 12 and above diagnosed with HIV. It is typically given via intramuscular injection every one or two months, based on the particular treatment regimen. The extended-release nature of these injections could enhance adherence among adolescents who find it difficult to follow daily pill routines.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21076
What regions are dominating the acquired immunodeficiency syndrome (aids) market growth?
North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired immunodeficiency syndrome (AIDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Pneumococcal Vaccine Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report
Vaccine Contract Manufacturing Global Market Report 2025
Cold Pain Therapy Global Market Report 2025
https://thebusinessresearchcompany.com/report/cold-pain-therapy-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
